Castleman病在70年发展历程的基础上，分型与诊疗体系正日趋完善。Castleman病患者中，iMCD亚型的诊疗更复杂，也需要更积极的治疗。抗IL-6疗法在iMCD治疗中处于一线地位，同时也是未来很长一段时间内研究的重要方向。司妥昔单抗是我国上市的首个且唯一获批治疗Castleman病的抗IL-6靶向药物，开启了我国免疫治疗的新通路，是我国Castleman病发展历程中的一项巨大进步，给我国患者带来了更多的治疗选择，也为疾病的良好控制提供了更多的可能。
1.Nishimura MF, Nishimura Y, Nishikori A, et al. Historical and pathological overview of Castleman disease. J Clin Exp Hematop. 2022;62(2):60-72.
2.Gaba AR , Stein RS , Sweet DL , et al.Multicentric giant lymph node hyperplasia [J] .Am J Clin Pathol , 1978 , 69 ( 1 ): 86 - 90.
3.van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010;8(7):486-498.（https://www.hematologyandoncology.net/archives/july-2010/castleman-disease-in-the-21st-century-an-update-on-diagnosis-assessment-and-therapy/）
4.van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-2124.
5.https://wenku.baidu.com/view/165579530266f5335a8102d276a20029bc646358.html?fr=aladdin664466&ind=1
6.中华医学会血液学分会淋巴细胞疾病学组,中国抗癌协会血液肿瘤专业委员会,中国CASTLEMAN病协作组.中国Castleman病诊断与治疗专家共识（2021年版）[J]. 中华血液学杂志,2021,42(7):529-534.
7.刘海玲,范磊,李建勇. Castleman病的诊疗进展[J]. 中华血液学杂志,2020,41(8):697-700.
8.Wang XQ, Zhong NN, Sun Q, et al. Comprehensive analysis of 65 patients with Castleman disease in a single center in China. Sci Rep. 2022;12(1):8694.
9.Zhang X, Rao H, Xu X, et al. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients. Cancer Sci. 2018;109(1):199-206.
10.Dong Y, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol. 2018 Sep;97(9):1641-1647.
11.https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480
12.van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020;7(3):e209-e217.
13.Zhang L, Zhang MY, Cao XX, et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leuk Lymphoma. 2022;63(3):618-626.
END
如需文献全文，请在下方留言并提供您的邮箱
